Other
Intravenous Administration
0
Pipeline Programs↗
4
Active Trials↗
19
Companies Involved↗
Intravenous Administration is an early-stage landscape with 0 programs across 19 companies. The most active players are Roche, Boehringer Ingelheim, Novartis.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
58
clinical trials
Completed39 · 67%
Unknown status6 · 10%
Terminated5 · 9%
Withdrawn3 · 5%
Recruiting3 · 5%
Suspended1 · 2%
Other1 · 2%
Clinical Trials
Trial Activity
58 trials
PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.
Completed·—·Phase 1·NCT01685333·28 enrolled
Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers
Completed·—·Phase 1·NCT07206043·130 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)